Results 11 to 20 of about 28,714 (188)
Tigecycline for severe Clostridium difficile infection [PDF]
International Journal of Infectious Diseases, 2014 Limited data suggest that tigecycline may be of value in the treatment of Clostridiumdifficile infection. We reviewed our experience using tigecycline to treat severe c.
Mark R Wallace, Nizam Uddin
exaly +4 more sources
Journal of Postgraduate Medicine, 2009 Infection with resistant pathogens can adversely affect clinical, microbiological and economic outcomes. New agents for the treatment of many such serious infections are acutely needed in hospital practice. Tigecycline is a novel glycylcycline antimicrobial for intravenous use.
Bhattacharya, M., Parakh, A., Narang, M.
core +7 more sources
Microbiology Spectrum, 2021 Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In this study, we investigated tigecycline heteroresistance in A.
Kwan Soo Ko
exaly +3 more sources
Five-Years Tigecycline Experience an Analysis of Real-Life Data [PDF]
Haseki Tıp Bülteni, 2018 Aim: Tigecycline has been approved by the Food and Drug Administration for the treatment of complicated intra-abdominal infections, skin and soft tissue infections and community-acquired pneumonia.
Fatih Temocin +8 more
doaj +2 more sources
PLoS ONE, 2015 KPC-producing Klebsiella pneumoniae isolates have emerged as important pathogens of nosocomial infections, and tigecycline is one of the antibiotics recommended for severe infections caused by KPC-producing K. pneumoniae.
Fang He +6 more
doaj +2 more sources
The first tigecycline resistant Enterococcus faecium in Norway was related to tigecycline exposure [PDF]
Journal of Global Antimicrobial Resistance, 2023 : Objectives: We describe the first tigecycline resistant enterococcal isolate in Norway and the mechanisms involved. Material and methods: The Norwegian National Advisory Unit on Detection of Antimicrobial Resistance (K-res).
Kristin Hegstad +4 more
doaj +3 more sources
Comparative Genomic Analysis of Tigecycline Resistance Development in Clinical Acinetobacter baumannii Isolates [PDF]
Infection and Drug ResistanceXiaoxia Li,1,* Junnian Liu,2,* Xinyu Zhang,1 Juan Li,3 Luhan Xuan,1 Sue Yuan,1 Jianglin Li,1 Yu Sun,1 Xuefei Du1 1Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of
Li X +8 more
doaj +1 more source
Drugs, 2005 Tigecycline is the first member of a new class of broad-spectrum antibacterials, the glycylcyclines, that has been specifically developed to overcome the two major mechanisms of tetracycline resistance (ribosomal protection and efflux). In vitro, tigecycline was active against a wide range of Gram-positive and -negative aerobic and anaerobic bacteria ...
James E, Frampton, Monique P, Curran
+8 more sources
Antibiotics, 2022 Acinetobacter baumannii is one of the main pathogens causing nosocomial and community-acquired infections. Tigecycline is an important antibiotic for the treatment of multidrug-resistant A.
Ping Wang +5 more
doaj +1 more source
Microbiology Spectrum, 2022 Acinetobacter baumannii is an important opportunistic pathogen of nosocomial infections. A. baumannii presently exhibits increasing antibiotic resistance, which poses great challenges to public health. The occurrence of tigecycline-resistant A. baumannii
Jiangang Zhang +8 more
doaj +1 more source